09:27 AM EDT, 06/06/2024 (MT Newswires) -- Nuwellis ( NUWE ) said Thursday it has extended its pilot program with dialysis services provider DaVita ( DVA ) until Aug. 31, to test its ultrafiltration therapy Aquadex for congestive heart failure patients.

The company said DaVita ( DVA ) is assessing the therapy's effectiveness in select US markets, focusing on high-need patients in hospitals. If successful, DaVita ( DVA ) may extend the supply agreement with Nuwellis ( NUWE ) for up to 10 years, Nuwelis added.

Shares of Nuwellis ( NUWE ) were up more than 8% in recent Thursday premarket activity, while DaVita ( DVA ) was up 0.3%.

Price: 0.2469, Change: +0.02, Percent Change: +8.38